Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer
about
The human plasma lipidomeLysophosphatidic acid plasma concentrations in healthy subjects: circadian rhythm and associations with demographic, anthropometric and biochemical parameters.Spiroguanidine rhodamines as fluorogenic probes for lysophosphatidic acid.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis.Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.Templated polymers enable selective capture and release of lysophosphatidic acid in human plasma via optimization of non-covalent binding to functional monomersExpressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma.Simple enrichment and analysis of plasma lysophosphatidic acids.The gep proto-oncogene Gα12 mediates LPA-stimulated activation of CREB in ovarian cancer cells.Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.Lysophosphatidic acid signaling in ovarian cancer.EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrolThe Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.Quantitation of phosphatidic acid and lysophosphatidic acid molecular species using hydrophilic interaction liquid chromatography coupled to electrospray ionization high resolution mass spectrometry.Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy.
P2860
Q26830940-07CC1361-1A00-4DB6-B396-43F2C38A91CEQ33922964-CEB20761-B69D-4905-AAD3-C41093508FE0Q35061819-EAF668A1-65A6-421A-9765-F8E3C294411FQ35837949-C636BD2C-A900-44BE-9267-ACA759A5A070Q35848103-DA48D42E-68B5-4354-882E-2FEB6B026B22Q36201267-E3763166-762B-452F-964E-E83ECEC9D37AQ36274382-C02904E2-278B-402A-8FCE-E82C35A909DDQ36411668-6A226AED-D483-48B0-8E95-1EBC7293137CQ37593579-E2A4B458-5149-4997-A77F-D91F5FED081EQ37711207-1E3C147A-8DCB-495D-8A79-033DF5C19CBEQ38470014-4A37F5C1-AC39-40D0-829F-1BA46BB3CA23Q38590952-EC033469-6AAA-40B6-948B-A436809BA50FQ39249383-72B0A35C-AEEF-4A82-AEF3-7C92B4D06FB9Q39411440-7608BA2D-0B51-4DC1-811F-B4EBC8718FCBQ43629218-7F8F689C-9D46-463C-AE94-CE46C3D4BBACQ49232671-9810154C-E3BA-49C1-A007-95B64DFB60FF
P2860
Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Comparison of total plasma lys ...... with epithelial ovarian cancer
@ast
Comparison of total plasma lys ...... with epithelial ovarian cancer
@en
Comparison of total plasma lys ...... with epithelial ovarian cancer
@nl
type
label
Comparison of total plasma lys ...... with epithelial ovarian cancer
@ast
Comparison of total plasma lys ...... with epithelial ovarian cancer
@en
Comparison of total plasma lys ...... with epithelial ovarian cancer
@nl
prefLabel
Comparison of total plasma lys ...... with epithelial ovarian cancer
@ast
Comparison of total plasma lys ...... with epithelial ovarian cancer
@en
Comparison of total plasma lys ...... with epithelial ovarian cancer
@nl
P2093
P2860
P1476
Comparison of total plasma lys ...... with epithelial ovarian cancer
@en
P2093
Cevdet Sanioglu
Elif Baykara
Fuat Demirkiran
Macit Arvas
Merve Barbaros
Salih Cengiz
Tugan Bese
P2860
P304
P356
10.3802/JGO.2010.21.4.248
P50
P577
2010-12-31T00:00:00Z